JPMorgan Downgrades Ethos Technologies to Neutral From Overweight, Price Target is $37

JPMorgan downgraded Ethos Technologies from Overweight to Neutral, setting a price target of $37. The stock has a 5-day change of -0.83% and a 1st Jan change of -1.00%.

Original reporting
Published Oct 1, 2026, 9:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 9:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$LIFE
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

Med
01

Why it matters

The downgrade reflects JPMorgan's revised expectations on valuation and earnings revisions, which may pressure the stock.

02

Market read

Analyst rating change could influence short-term trading sentiment.

03

What to watch

Potential pipeline milestones not mentioned in the note.

Relevance 7/10Novelty 6/10Timing: pre-market today

Background

JPMorgan lowered its rating on Ethos Technologies to Neutral from Overweight and set a new price target of $37.

Market effects

Analyst downgrade may weigh on the biotech sector.

Limited to US markets where the stock trades.

Minimal global impact.

Counterpoint

The downgrade could be premature if upcoming data beats expectations.

Key entities

  • JPMorgan

    Issued the downgrade and new price target.

  • Ethos Technologies

    Subject of the downgrade.

Related articles

$LIFEMed

Ethos (LIFE) Grows Revenue 113% While Margins Quietly Compress

Ethos Technologies (LIFE) reported Q2 revenue growth of 113% to $189.6M, with new policies up 133%. Gross profit margin was 98%, but net income rose only 5% to $19.5M. The company authorized a $100M stock buyback. Q3 revenue guidance is $160M-$164M, and full-year guidance is $727M-$731M. Margins compressed, with GAAP net loss of $146.9M for H1 2026 due to stock-based compensation.

$LIFEMedAI 9/10

Ethos (LIFE) Q2 2026 Earnings Call Transcript

Ethos Technologies (LIFE) reported Q2 2026 revenue of $189.6 million, up 113% Y/Y, with direct revenue $116.5 million (+131%) and third-party revenue $73.1 million (+90%). Adjusted EBITDA was $35.2 million (19% margin). Net income was $19.5 million. Full-year 2026 guidance: revenue $727-$731 million and adjusted EBITDA $119-$123 million. Up to $100 million Class A repurchase authorized.

$LIFEMed

Top SMid Cap Pick: Ethos Technologies Leads Citi’s Rankings

Citi analyst Ronald Josey named Ethos Technologies (LIFE) his top SMID-cap pick after the company’s Q2 results. Activated policies growth accelerated to 133% YoY, with 107,800 net activated policies. Revenue rose to $189.6M (+113% YoY). Ethos raised 2026 revenue guidance to $727M-$731M and adjusted EBITDA to $119M-$123M. Citi lifted its price target to $33 and kept Buy/High Risk.

$LIFEHigh

Ethos Reports Second Quarter Fiscal Year 2026 Financial Results

Ethos Technologies Inc. (LIFE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ethos Reports Second Quarter Fiscal Year 2026 Financial Results • Q2 Revenue grew 113% year-over-year to $190 million • Q2 Direct Channel Revenue grew 131% year-over-year to $116 million • Q2 Third-Party Revenue grew 90% year-over-year to $73 million • Board of Direc